[Lu]-DOTA-Tyr-octreotate: A Potential Targeted Radiotherapeutic for the Treatment of Medulloblastoma.
Medulloblastoma, the most common pediatric brain tumor, is difficult to treat because conventional therapeutic approaches result in significant toxicity to normal central nervous system tissues, compromising quality of life. Given the fact that medulloblastomas express the somatostatin subtype 2 receptor, [(177)Lu-DOTA(0),Tyr(3)]octreotate ([(177)Lu]DOTA-TATE) could be a potentially useful targeted radiotherapeutic for the treatment of this malignancy. The current study was undertaken to evaluate this possibility in preclinical models of D341 MED human medulloblastoma by comparing the properties of [(177)Lu]DOTA-TATE to those of glucose-[(125)I-Tyr(3)]-octreotate ([(125)I]Gluc-TOCA), a radiopeptide previously shown to target this cell line. In vitro assays indicated that both labeled peptides exhibited similar cell-associated and internalized radioactivity after a 30-min incubation at 37°C; however, at the end of the 4 h incubation period, the internalized radioactivity for [(177)Lu]DOTA-TATE (6.22 " 0.75%) was nearly twice that for [(125)I]Gluc-TOCA (3.16 " 0.27%), with similar differences seen in total cell-associated radioactivity levels. Consistent with the results from the internalization assays, results from paired-label tissue distribution studies in athymic mice with subcutaneous D341 MED medulloblastoma xenografts showed a similar degree of tumor accumulation for [(177)Lu]DOTA-TATE and [(125)I]Gluc-TOCA at early time points but by 24 h, a more than 5-fold advantage was observed for the (177)Lu-labeled peptide. Tumor-to-normal tissue ratios generally were more favorable for [(177)Lu]DOTA-TATE at all time points, due in part to its lower accumulation in normal tissues except kidneys. Taken together, these results suggest that [(177)Lu]DOTA-TATE warrants further investigation as a targeted radiotherapeutic for medulloblastoma treatment.
Department of Radiology Duke University Medical Center, Durham, North Carolina, USA 27710.
Ganesan
G
Vaidyanathan
Donna J
DJ
Affleck
Xiao-Guang
XG
Zhao
Stephen T
ST
Keir
Michael R
MR
Zalutsky
Clin Cancer Res. 2003 May;9(5):1868-76
12738745
J Clin Oncol. 2008 May 1;26(13):2124-30
18445841
Cancer Biother Radiopharm. 2008 Feb;23(1):114-20
18298335
Int J Cancer. 2001 Dec 15;94(6):873-7
11745491
Cancer Res. 1990 Feb 1;50(3 Suppl):1043s-1048s
2297718
Am J Pathol. 1988 Mar;130(3):472-84
3279793
Acta Oncol. 2007;46(6):723-34
17653893
Pediatr Res. 1999 May;45(5 Pt 1):697-708
10231868
Acta Oncol. 2007;46(1):111-7
17438713
Endocrinology. 1995 Sep;136(9):3698-706
7649075
J Neurooncol. 2001 Jan;51(2):93-103
11386415
Cancer Biother Radiopharm. 2005 Apr;20(2):231-6
15869461
Cancer Treat Rev. 2009 Feb;35(1):79-96
18976866
Appl Radiat Isot. 2008 Feb;66(2):147-51
17900914
Cancer Biother Radiopharm. 2003 Oct;18(5):761-8
14629824
J Clin Oncol. 2005 Apr 20;23(12):2754-62
15837990
Cancer Res. 1998 Feb 1;58(3):437-41
9458086
J Clin Oncol. 2007 Dec 1;25(34):5465-70
18048828
J Neuroendocrinol. 2002 Jun;14(6):458-71
12047721
J Clin Oncol. 2001 Aug 1;19(15):3470-6
11481352
Eur J Cancer. 2002 May;38(8):1112-20
12008200
Eur J Nucl Med Mol Imaging. 2003 Oct;30(10):1338-47
12937948
Eur J Nucl Med Mol Imaging. 2003 Jun;30(6):917-20
12677301
Hybridoma (Larchmt). 2009 Dec;28(6):389-403
20025498
Clin Cancer Res. 2004 May 1;10(9):2997-3006
15131035
J Nucl Med. 1995 Apr;36(4):623-7
7699456
Eur J Nucl Med. 1999 Jul;26(7):693-8
10398816
Eur J Nucl Med. 2001 Sep;28(9):1319-25
11585290
Anticancer Res. 2007 Nov-Dec;27(6B):3941-6
18225554
Best Pract Res Clin Endocrinol Metab. 2007 Mar;21(1):111-29
17382268
J Neurooncol. 1998 May;38(1):27-40
9540055
Bioconjug Chem. 2007 Nov-Dec;18(6):2122-30
17979223
Bioconjug Chem. 2006 Jan-Feb;17(1):195-203
16417269
Cancer. 2005 Feb 15;103(4):869-73
15641034
Peptides. 2004 Dec;25(12):2087-97
15572196
J Nucl Med. 2005 Sep;46(9):1561-9
16157541
Pediatr Blood Cancer. 2008 Mar;50(3):561-6
17387742
Arch Neurol. 2008 Nov;65(11):1419-24
19001159
Appl Radiat Isot. 2007 Mar;65(3):301-8
17110119
Cancer Biother Radiopharm. 2003 Aug;18(4):593-9
14503955
Eur J Nucl Med Mol Imaging. 2003 Mar;30(3):417-22
12634971
Bioorg Med Chem Lett. 1998 May 19;8(10):1207-10
9871736